Last updated: February 17, 2026
Litigation Summary and Analysis for Custopharm Inc. v. Fresenius Kabi USA, LLC | 6:21-cv-00148
Case Overview
Custopharm Inc. filed a patent infringement lawsuit against Fresenius Kabi USA, LLC on January 29, 2021, in the U.S. District Court for the Northern District of Texas. The case, docket number 6:21-cv-00148, centers on alleged infringement of U.S. Patent No. 10,607,831 ('831 patent). The patent pertains to methods and formulations related to the sterilization and preparation of ready-to-use (RTU) pharmaceutical products, specifically involving aseptic transfer and stability enhancements.
Patent Details
- Patent Number: 10,607,831
- Filing Date: August 27, 2019
- Issue Date: March 3, 2020
- Assignee: Custopharm Inc.
- Scope: Focuses on methods for sterilizing and preparing pharmaceutical solutions, including specific formulations and aseptic techniques designed to extend product shelf life.
Allegations
Custopharm alleges Fresenius Kabi’s use of a process similar to that covered by the '831 patent in its manufacturing of certain sterile drug products. The complaint claims infringement through the use of specific aseptic transfer techniques and formulations that meet the patent's claims.
Defense and Early Motions
As of the latest update, Fresenius Kabi has filed a motion to dismiss the complaint for failure to state a claim under Federal Rule of Civil Procedure 12(b)(6). The company argues that the patent's claims are indefinite and lack patentable subject matter under 35 U.S.C. § 101. It also contends that the claims are overly broad and not supported by the specification.
Court Proceedings
- Status: The court has scheduled a claim construction hearing for July 2023.
- Key Issues:
- Validity of the '831 patent, particularly under § 101.
- Scope of the patent claims, including whether they cover Fresenius Kabi’s products and processes.
- Whether the patent claims are sufficiently definite.
Legal Context and Potential Outcomes
Custopharm's win hinges on demonstrating that its patent claims are valid, clear, and infringed. Fresenius Kabi’s defenses focus on patent invalidity, particularly on the grounds that the claims are indefinite or not patentable. The outcome may influence industry standards for aseptic transfer methods and formulating sterile drugs, especially if the patent withstands validity challenges.
Comparative Analysis
- Patent Validity Challenges: The validity arguments reflect a common trend in sterile drug patent litigations, where defendants challenge the scope and patentability of functional claims.
- Industry Impact: Successful defense by Fresenius could set a precedent for narrowing claims related to aseptic processes, influencing future patent drafting and litigation strategies.
Key Takeaways
- Custopharm's patent relates to aseptic transfer and sterilization processes specific to sterile pharmaceutical products.
- Fresenius Kabi’s defense centers on patent validity, focusing on issues of indefiniteness and patentable subject matter.
- The case’s resolution could clarify standards for patent claim scope in sterile product manufacturing.
- The scheduled claim construction hearing indicates ongoing contention over the patent's language and scope.
- A final judgment will affect licensing and manufacturing practices in the sterile pharmaceutical industry.
FAQs
Q1: What are the main legal grounds for Fresenius Kabi's challenge?
They challenge the patent on grounds of indefiniteness and patent-eligible subject matter under 35 U.S.C. § 101.
Q2: How does this case compare to similar patent disputes in the pharmaceutical industry?
It follows common patterns where defendants dispute patent validity based on claim scope, patentable subject matter, and written description adequacy.
Q3: What impact could this case have on sterilization patent filings?
A favorable ruling for Custopharm could reinforce claims on aseptic transfer methods, encouraging broader patent protections in sterile pharmaceutical manufacturing.
Q4: When is the court expected to decide the motion to dismiss?
The resolution of the motion is pending the court’s ruling after the scheduled claim construction hearing scheduled for July 2023.
Q5: Could this case influence licensing negotiations in the industry?
Yes. A ruling upholding the patent’s validity may foster licensing agreements, whereas invalidation could lead to patent challenges or design-arounds in sterile manufacturing.
References
[1] Custopharm Inc. v. Fresenius Kabi USA, LLC, 6:21-cv-00148 (N.D. Texas, filed Jan 29, 2021).
[2] U.S. Patent No. 10,607,831.
[3] Federal Rules of Civil Procedure, Rule 12.
